人卵巢癌组织中MAP3K3 mRNA的表达及预后分析  

Expression of MAP3K3 mRNA and its prognosis in human ovarian carcinoma

作　　者：尹灿[1] 张莹[1] 董玉玲 陶林[1] 邹泓[1] 梁伟华[1] 赵瑾[1] 李锋[1,2] 贾薇 YIN Can1, ZHANG Ying1 , DONG Yu-ling1 , TAO Lin1 , ZOU Hong1 , LIANG Wei-hua1 , ZHAO Jin1 , LI Feng1,2 , JIA Wei1(1Department of Pathology, Shihezi University Medical School, Shihezi 832002, China ; 2Department of Pathology, Beijing Chaoyang Hospital, Beijing 100020, Chin)

机构地区：[1]石河子大学医学院病理系/第一附属医院病理科,石河子832002 [2]北京朝阳区医院病理科,北京100020

出　　处：《临床与实验病理学杂志》2018年第3期248-252,共5页Chinese Journal of Clinical and Experimental Pathology

基　　金：国家自然科学基金(81660431);人力资源和社会保障部项目基金(2016LX008)

摘　　要：目的探讨有丝分裂原活化蛋白激酶激酶激酶3(mitogen-activated protein kinase kinase kinase 3,MAP3K3)的mRNA表达与卵巢癌临床病理特征及预后的相关性。方法采用qRT-PCR法检测MAP3K3 mRNA在卵巢癌和输卵管组织中的表达,并分析其差异表达与临床病理特征的关系,评价MAP3K3 mRNA表达在卵巢癌患者预后中的价值。结果 MAP3K3 mRNA在卵巢癌组织中的表达显著高于输卵管组织(P<0.05),其高表达与卵巢癌FIGO分期及发病模式分型相关(P<0.05);KaplanMeier生存分析显示,MAP3K3 mRNA高表达患者的无瘤生存时间和总体生存时间均显著短于低表达患者(中位生存时间:34个月vs 52.2个月,P<0.05;38.6个月vs 52.5个月,P<0.05);单因素分析显示,MAP3K3 mRNA高表达与卵巢癌患者预后差相关(HR=4.198,95%CI:1.711~10.302,P<0.05)。结论 MAP3K3 mRNA在卵巢癌组织中高表达,其高表达与卵巢癌FIGO分期、发病模式及预后差呈正相关,可能参与了卵巢癌的恶性转化。Purpose To investigate the expression of mito- gen-activated protein kinase kinase kinase 3 （MAP3K3） mRNA in ovarian carcinoma patients and to explore the correlation a- mong its expression, clinicopathological features and prognosis. Methods The expression of MAP3K3 mRNA in ovarian carci- noma and fallopian tube tissues were detected by qRT-PCR, and the correlation between MAP3K3 mRNA expression and clinico- pathological features was also analyzed. Whether MAP3K3 mR- NA expression could be used as an independent predictor of prognosis for patients with ovarian carcinoma was further deter- mined. Results The expression of MAP3K3 mRNA in ovarian carcinoma was significantly higher than that in fallopian tube tis- sues （P 〈0. 05）. High expression of MAP3K3 mRNA was sig- nificantly correlated with FIGO stage and Challenge model of o-varian carcinoma （ P 〈 0. 05 ）. Kaplan-Meier survival analysis showed that the disease-free survival time and overall survival time of patients with high MAP3K3 mRNA expression were shor- ter than those with low expression （ 34 months vs 52.2 months, P 〈 0. 05. 38, 6 months vs 52. 5 months, P 〈 0. 05）. Univariate analysis showed that high expression of MAP3K3 mRNA was a risk factor for poor prognosis of ovarian carcinoma patients （ HR =4. 198, 95% CI： 1. 711 - 10. 302, P 〈0. 05）. Conclusion MAP3K3 mPtNA is highly expressed in ovarian carcinoma tis- sues. Its high expression is associated with FIGO stage, Chal- lenge model and poor prognosis of ovarian carcinoma, which may involve in the malignant transformation of ovarian carcinoma.

关 键 词：卵巢肿瘤 MAP3K3 MRNA 预后 

分 类 号：R737.31[医药卫生—肿瘤]